Conference Coverage

Study: No link between vaccines, inhibitor development


 

FROM EAHAD 2017

The administration of pediatric vaccinations in close proximity to factor VIII (FVIII) exposure was not associated with inhibitor development in previously untreated patients with severe hemophilia A in the PedNet Registry.

Vaccine syringe copyright luiscar/Thinkstock
Of 232 patients from the registry who received vaccinations within 48 hours before or 24 hours after FVIII exposure, 38 (16.4%) developed inhibitors, compared with 39 (27.3%) of 143 who did not receive vaccinations within that time frame (adjusted hazard ratio for any inhibitor development related to vaccinations in close proximity to FVIII, 0.65), according to H. Marijke van den Berg, MD of University Medical Centre, Utrecht, The Netherlands.

Similarly, no association was seen between recurrent vaccinations and inhibitor development, Dr. van den Berg reported at the annual meeting of the European Association for Haemophilia and Allied Disorders.

Inhibitor development in this patient population is a multifactorial event, but these findings show no association between vaccinations administered early in life and increased inhibitor risk, she concluded.

Dr. van den Berg received grant/research support from Bayer, Baxalta, Pfizer, CSI, and Grifols.

Recommended Reading

VIDEO: Novel microcapsules show promise in hemophilia A with inhibitory antibodies
MDedge Hematology and Oncology
VIDEO: Hemophilia B gene therapy maintains factor IX levels averaging 28%
MDedge Hematology and Oncology
VIDEO: Artificial blood cells clear first phase of animal testing
MDedge Hematology and Oncology
Microsensor perfectly distinguished coagulopathy patients from controls
MDedge Hematology and Oncology
VIDEO: Point-of-care microsensor prototype beats conventional coagulopathy tests
MDedge Hematology and Oncology
Ruxolitinib beats best available care for hematocrit control in polycythemia
MDedge Hematology and Oncology
Sickle cell trait artificially lowers HbA1c
MDedge Hematology and Oncology
AHEAD studies establish bleed rate benchmarks
MDedge Hematology and Oncology
Drug granted fast track designation for PNH
MDedge Hematology and Oncology
EC grants drug orphan designation for PNH
MDedge Hematology and Oncology